Article

Elotuzumab in combination with thalidomide and low‐dose dexamethasone: a phase 2 single‐arm safety study in patients with relapsed/refractory multiple myeloma

British Journal of Haematology, Wiley, ISSN 1365-2141

Volume 175, 3, 2016

DOI:10.1111/bjh.14263, Dimensions: pub.1025341598, PMID: 27434748,

Affiliations

Organisations

  1. (1) Instituto de Investigación Biomédica de Salamanca, grid.452531.4
  2. (2) Haematology Department Hospital de la Santa Creu i Sant Pau Barcelona Spain
  3. (3) Catalan Institute of Oncology, grid.418701.b
  4. (4) Hospital Universitario 12 De Octubre, grid.144756.5
  5. (5) Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, grid.10403.36
  6. (6) Hospital Universitario de Canarias, grid.411220.4
  7. (7) Hospital Universitario Virgen del Rocío, grid.411109.c
  8. (8) Hospital Universitari Vall d'Hebron, grid.411083.f
  9. (9) Bristol-Myers Squibb (United States), grid.419971.3
  10. (10) AbbVie Biotherapeutics Inc. (ABR) Redwood City CA USA
  11. (11) Clinical and Translational Medicine Clínica Universidad de Navarra – CIMA (Centro de Investigación Médica Aplicada) – IdiSNA (Instituto de Investigación Sanitaria de Navarra) Pamplona Spain

Funders

Research Categories

Main Subject Area

Fields of Research

Links & Metrics

NORA University Profiles

University of Southern Denmark

Dimensions Citation Indicators

Times Cited: 32

Field Citation Ratio (FCR): 13.98

Relative Citation ratio (RCR): 2.08